Add like
Add dislike
Add to saved papers

Ear lobe keloids, surgical excision followed by radiation therapy: a 10-year experience.

This retrospective study was conducted to analyze the recurrence of ear lobe keloids in 36 patients after surgical excision followed by radiation therapy. In all the cases keloids were excised and the surgical wound closed primarily. Following surgery, patients underwent 1800 cGy of radiation therapy in three equally divided doses over five to seven days. Most of our patients were young black females who developed keloids secondary to ear lobe piercing. Of the 36 patients followed for a mean period of 5.6 years, we noted only one (2.8%) recurrence. All the patients were followed for a minimum of two years. No serious complications were observed in our series. However, one patient developed radiation dermatitis followed by patchy hypopigmentation. We conclude that surgical excision followed by radiation therapy is a safe and effective method to control keloid recurrence in the ear lobe region.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app